{"publication_id":"ad6bd204-1859-4516-b412-8f3a7f40f350","content_hash":"sha256:7ae5a315ae658da48e93a33c1241916c042f53feec57cfb3425080c47968322b","nodes":[{"id":"ad6bd204-1859-4516-b412-8f3a7f40f350","type":"publication","title":"Research Synthesis: Senescence Cancer Effects — full paper"},{"id":"claim_1","type":"claim","text":"This paper synthesizes evidence on senescence cancer effects across 13 accepted source papers and 220 high-confidence extracted claims."},{"id":"claim_2","type":"claim","text":"The evidence profile contains no sources classified primarily as direct clinical evidence, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 0 cross-study disagreements across the evidence base."},{"id":"claim_3","type":"claim","text":"No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, muscle function, immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_4","type":"claim","text":"The conclusion is that senescence cancer effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_5","type":"claim","text":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-senescence_cancer_effects-v06-DAILY-2026-06-16T11-52-36Z`."},{"id":"claim_6","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_7","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses)."},{"id":"claim_8","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, frailty, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_9","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_10","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_11","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_12","type":"claim","text":"| Contextual Adjacent Evidence | n=8; claims=156 | no extracted directional signal in 7/8 sources | 7 indirect; 1 review | limited corpus depth in this outcome class |"},{"id":"claim_13","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_14","type":"claim","text":"8 included sources were assigned to this outcome class. Directional coding: null=7, unclear=1. Directness coding: indirect=7, review=1."},{"id":"claim_15","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=1, unclear=1. Directness coding: indirect=1, review=1."},{"id":"claim_16","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1."},{"id":"claim_17","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_18","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_19","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_20","type":"claim","text":"The curated corpus lacks randomized controlled trials (RCTs) directly testing senescence-targeting interventions against cancer outcomes, creating a critical gap in establishing causal efficacy. The absence of long-term mortality or recurrence trials in adults with or without cancer limits the ability to translate biomarker associations into clinically actionable endpoints, leaving the boundary conditions for senescence modulation undefined. This limitation is compounded by the inclusion of only one study (Moskalevska 2026) examining longevity outcomes, which reports a 20% survival increase in males but lacks replication in broader populations, further constraining generalizability."},{"id":"claim_21","type":"claim","text":"Single-trial dominance for specific outcomes introduces replication risk and undermines the robustness of headline conclusions. These isolated observations cannot support definitive claims about senescence-targeting strategies without corroborating evidence across multiple independent cohorts."},{"id":"claim_22","type":"claim","text":"Population specificity severely constrains the external validity of the synthesized evidence, particularly for high-risk or underrepresented groups. The majority of included studies (e.g., Fielding 2022, Blomquist 2026, Shah 2025) focus on general adult or type 2 diabetes populations, with Shah 2025 explicitly limited to post-myocardial infarction patients with diabetes. This narrow enrollment excludes individuals with other comorbid conditions, varying cancer subtypes, or diverse ethnic backgrounds, where senescence-cancer interactions may differ. The absence of trials enrolling non-white populations or those with early-stage cancers further limits the applicability of findings to global demographics, where cancer incidence and senescence biology exhibit substantial heterogeneity. Even studies targeting older adults (e.g., Castillo 2026) rely on frailty frameworks (e.g., Fried et al.) that may not capture the full spectrum of aging-related senescence in oncology."},{"id":"claim_23","type":"claim","text":"The corpus exhibits a pronounced mechanistic-to-clinical translation gap, where senescence-related claims are supported by preclinical or indirect human data without corresponding clinical validation. For example, Lin 2021 and Fang 2023 link senescence patterns to immunotherapeutic responses and cancer outcomes, respectively, but these associations are not grounded in trials demonstrating that targeting senescence (e.g., via senolytics) improves clinical endpoints. Similarly, Moskalevska 2026 reports healthspan and survival benefits in animal models, yet these findings are not replicated in human RCTs, leaving the clinical feasibility of senescence-targeting strategies uncertain. This disconnect is exacerbated by the inclusion of mechanistic reviews (e.g., Sobolewski 2026) that highlight histological markers without demonstrating their actionability in patient care, further widening the chasm between bench and bedside."},{"id":"claim_24","type":"claim","text":"For senescence cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_25","type":"claim","text":"This synthesis maps 13 included sources on Senescence across 5 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_26","type":"claim","text":"Across 13 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Null findings dominate: contextual other, muscle function. The Senescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_27","type":"claim","text":"Prior reviews in the corpus (Moskalevska 2026) emphasize convergent signals on Senescence. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_28","type":"claim","text":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |"},{"id":"claim_29","type":"claim","text":"| contextual adjacent evidence | 0 | 8 | null, unclear | direct interventional hard-endpoint gap |"},{"id":"claim_30","type":"claim","text":"| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |"},{"id":"source_1","type":"source","study":"CD57 + EMRA CD8 + T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy","year":2024,"doi":"10.1186/s12979-024-00487-4","url":"https://doi.org/10.1186/s12979-024-00487-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study","year":2022,"doi":"10.1007/s11357-022-00685-2","url":"https://doi.org/10.1007/s11357-022-00685-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence","year":2024,"doi":"10.1186/s12967-024-05814-3","url":"https://doi.org/10.1186/s12967-024-05814-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy","year":2025,"doi":"10.3389/fimmu.2025.1566227","url":"https://doi.org/10.3389/fimmu.2025.1566227","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study","year":2026,"doi":"10.3390/ijms27104406","url":"https://doi.org/10.3390/ijms27104406","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction","year":2025,"doi":"10.1111/dme.70059","url":"https://doi.org/10.1111/dme.70059","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study","year":2026,"doi":"10.3390/cancers18111710","url":"https://doi.org/10.3390/cancers18111710","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method","year":2023,"doi":"10.3389/fendo.2023.1255889","url":"https://doi.org/10.3389/fendo.2023.1255889","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults—A Narrative Review","year":2026,"doi":"10.3390/biomedicines14040875","url":"https://doi.org/10.3390/biomedicines14040875","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_10","type":"source","study":"Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review","year":2026,"doi":"10.3390/ijms27031520","url":"https://doi.org/10.3390/ijms27031520","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_11","type":"source","study":"Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma","year":2021,"doi":"10.1186/s12935-021-02358-0","url":"https://doi.org/10.1186/s12935-021-02358-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Targeting the senescence-associated immune checkpoint GD3 ganglioside extends healthspan and blunt age-related diseases with sex-specific benefits","year":2026,"doi":"10.64898/2026.01.06.697856","url":"https://doi.org/10.64898/2026.01.06.697856","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers","year":2025,"doi":"10.3389/fgene.2024.1461404","url":"https://doi.org/10.3389/fgene.2024.1461404","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"**Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.","year":2011,"doi":"10.1001/jama.2010.1923","url":"https://doi.org/10.1001/jama.2010.1923","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"**Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.","year":2019,"doi":"10.1093/ageing/afy169","url":"https://doi.org/10.1093/ageing/afy169","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.","year":2005,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"**ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.","year":2024,"doi":"10.2337/dc24-s006","url":"https://doi.org/10.2337/dc24-s006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_18","type":"source","study":"**Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993.","year":2000,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_19","type":"source","study":"**Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.","year":2008,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_20","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_21","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_22","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_23","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_1","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_2","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_3","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_4","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_5","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_6","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_7","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_8","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_9","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_10","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_11","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_12","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_13","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_14","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_15","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_16","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_17","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_18","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_19","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_20","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_21","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_22","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_23","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_24","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_25","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_26","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_27","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_28","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_29","type":"contains_claim"},{"from":"ad6bd204-1859-4516-b412-8f3a7f40f350","to":"claim_30","type":"contains_claim"}],"screening":{"identified":22,"screened":22,"excluded":0,"included":22,"included_or_retained":22,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"22 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}